Plain language summary of the EMPEROR-Preserved study looking at the effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Future cardiology Pub Date : 2023-12-01 Epub Date: 2023-11-23 DOI:10.2217/fca-2023-0080
Javed Butler, Gerasimos Filippatos
{"title":"Plain language summary of the EMPEROR-Preserved study looking at the effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes.","authors":"Javed Butler, Gerasimos Filippatos","doi":"10.2217/fca-2023-0080","DOIUrl":null,"url":null,"abstract":"<p><strong>What is this study about?: </strong>The EMPEROR-Preserved study looked at the effects of empagliflozin in participants with heart failure with a preserved ejection fraction (HFpEF). This is when the lower left part of the heart (left ventricle) squeezes normally or near normally but does not fill with enough blood between heartbeats. Therefore, not enough blood is pumped around the body. For this study, HFpEF was defined as a condition in which more than 40% of blood in the left ventricle was pumped around the body. When researchers started the EMPEROR-Preserved study, there was no treatment for HFpEF. Also, researchers did not know if empagliflozin was more or less effective in people with and without diabetes, a condition where there are high levels of sugar (glucose) in the blood. This study included participants with HFpEF with and without diabetes to see if empagliflozin had a positive effect on the heart compared with a placebo (a pill that looked like empagliflozin but did not contain any active medication). Nearly 50% of participants had diabetes. The researchers looked at: How many people needed to be hospitalized for heart failure (HF) or died from conditions that affect the heart and blood vessels (cardiovascular disease) If peoples' kidneys worked less over time (the decline in kidney function) The side effects of empagliflozin.</p><p><strong>What were the study results?: </strong>Empagliflozin reduced the risk of either being hospitalized for HF or dying from cardiovascular disease. The decrease in this risk was due to fewer hospitalizations for HF. This was true regardless of whether or not participants had diabetes. Empagliflozin also slowed the decline in kidney function, regardless of whether the participant had diabetes, but the effect was larger in participants with diabetes. There were no differences in side effects in participants taking empagliflozin or placebo, and the results were similar regardless of whether or not participants had diabetes.</p><p><strong>What do these study results mean?: </strong>The results showed that treatment with empagliflozin reduced the risk of hospitalization for HF and there were no major side effects in participants with HFpEF, regardless of whether or not they had diabetes.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/fca-2023-0080","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

What is this study about?: The EMPEROR-Preserved study looked at the effects of empagliflozin in participants with heart failure with a preserved ejection fraction (HFpEF). This is when the lower left part of the heart (left ventricle) squeezes normally or near normally but does not fill with enough blood between heartbeats. Therefore, not enough blood is pumped around the body. For this study, HFpEF was defined as a condition in which more than 40% of blood in the left ventricle was pumped around the body. When researchers started the EMPEROR-Preserved study, there was no treatment for HFpEF. Also, researchers did not know if empagliflozin was more or less effective in people with and without diabetes, a condition where there are high levels of sugar (glucose) in the blood. This study included participants with HFpEF with and without diabetes to see if empagliflozin had a positive effect on the heart compared with a placebo (a pill that looked like empagliflozin but did not contain any active medication). Nearly 50% of participants had diabetes. The researchers looked at: How many people needed to be hospitalized for heart failure (HF) or died from conditions that affect the heart and blood vessels (cardiovascular disease) If peoples' kidneys worked less over time (the decline in kidney function) The side effects of empagliflozin.

What were the study results?: Empagliflozin reduced the risk of either being hospitalized for HF or dying from cardiovascular disease. The decrease in this risk was due to fewer hospitalizations for HF. This was true regardless of whether or not participants had diabetes. Empagliflozin also slowed the decline in kidney function, regardless of whether the participant had diabetes, but the effect was larger in participants with diabetes. There were no differences in side effects in participants taking empagliflozin or placebo, and the results were similar regardless of whether or not participants had diabetes.

What do these study results mean?: The results showed that treatment with empagliflozin reduced the risk of hospitalization for HF and there were no major side effects in participants with HFpEF, regardless of whether or not they had diabetes.

简明扼要地总结EMPEROR-Preserved研究,观察恩格列净对保留射血分数的心力衰竭患者(伴和不伴糖尿病)的影响。
这项研究是关于什么的?: EMPEROR-Preserved研究观察了恩格列净对保留射血分数(HFpEF)的心力衰竭患者的影响。这是指心脏的左下部分(左心室)正常或接近正常挤压,但心跳之间没有足够的血液。因此,没有足够的血液被泵入全身。在这项研究中,HFpEF被定义为左心室40%以上的血液被泵送到全身的情况。当研究人员开始EMPEROR-Preserved研究时,还没有治疗HFpEF的方法。此外,研究人员也不知道恩格列净对糖尿病患者或非糖尿病患者是否更有效。糖尿病是一种血液中糖(葡萄糖)水平较高的疾病。这项研究包括有和没有糖尿病的HFpEF参与者,以观察恩帕列净与安慰剂(一种看起来像恩帕列净但不含任何活性药物的药丸)相比是否对心脏有积极作用。近50%的参与者患有糖尿病。研究人员观察了:有多少人需要因心力衰竭(HF)住院或死于影响心脏和血管的疾病(心血管疾病)如果人们的肾脏随着时间的推移工作减少(肾功能下降)恩格列净的副作用。研究结果如何?恩帕列净降低了因心衰住院或死于心血管疾病的风险。这种风险的降低是由于心衰住院的减少。无论参与者是否患有糖尿病,这都是正确的。恩帕列净也减缓了肾功能的下降,无论参与者是否患有糖尿病,但糖尿病参与者的效果更大。服用恩格列净或安慰剂的受试者的副作用没有差异,而且无论受试者是否患有糖尿病,结果都是相似的。这些研究结果意味着什么?结果显示,恩格列净治疗降低了HF住院的风险,并且无论是否患有糖尿病,HFpEF患者都没有主要的副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future cardiology
Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.80
自引率
5.90%
发文量
87
期刊介绍: Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信